[{"id":"4726144b-81f2-4e03-a436-9f3e157490f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05287308","created_at":"2022-03-18T11:54:32.871Z","updated_at":"2024-07-02T16:36:14.315Z","phase":"","brief_title":"Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study","source_id_and_acronym":"NCT05287308","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Pinorubin (pirarubicin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2022-03-31"},{"id":"08eacf90-f860-42e0-8a30-4b21625379a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04437160","created_at":"2021-01-18T21:21:40.977Z","updated_at":"2024-07-02T16:36:43.993Z","phase":"Phase 2","brief_title":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","source_id_and_acronym":"NCT04437160","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • epirubicin • Pinorubin (pirarubicin) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 286","initiation":"Initiation: 02/01/2020","start_date":" 02/01/2020","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2020-06-19"},{"id":"b869532b-4b47-474d-a303-9692e3af1ab0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02838225","created_at":"2021-01-18T13:55:41.484Z","updated_at":"2024-07-02T16:37:30.412Z","phase":"Phase 2","brief_title":"DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer","source_id_and_acronym":"NCT02838225","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • Pinorubin (pirarubicin) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 300","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2016-07-20"}]